Sanofi will pay US$15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based closing price on Tuesday. The Dynavax deal gives Sanofi a hepatitis B vaccine that’s already marketed in the US, as well as an experimental shingles inoculation currently in early human testing. Still, Sanofi has inked the deal despite difficulties in the global vaccination market. One type, called secondary progressive MS, which involves which involves a steady increase in disability, is what Sanofi’s FDA application targets. There are currently few treatments for this type of MS. Sanofi said it is committed to working with the FDA to find a path forward for the drug.

Source: The Edge Markets December 24, 2025 08:26 UTC